Fig. 1: Vaccine reactogenicity.
From: Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Maximum severity reported of injection site (local) and systemic solicited reactions for Ad26.COV2.S-primed, mRNA-1273-primed and BNT162b2-primed participants boosted with NVX-CoV2373. Symptoms were reported as absent, mild, moderate, or severe in the 7 days after NVX-CoV2373 vaccination.
